Glenmark Pharma ends higher on receiving USFDA nod for Calcipotriene Cream

India Infoline News Service | Mumbai | May 04, 2015 16:34 IST

Glenmark will market this product upon receiving final approval of its Calcipotriene Cream, 0.005% ANDA.

Glenmark Pharmaceuticals advanced 2% to Rs. 908 on BSE after the company received tentative approval by the United States Food & Drug Administration (USFDA) for Calcipotriene Cream, 0.005 percent.
The stock has hit a high of Rs. 929 and a low of Rs. 828.
Glenmark will market this product upon receiving final approval of its Calcipotriene Cream, 0.005% ANDA.  The patents listed in the Orange Book for Dovonex® Cream are scheduled to expire on June 9, 2015.

***Note: This is a NSE Chart

 

Advertisements

  • Save upto Rs.2.67 lakh with Pradhan Mantri Awas Yojana ...Know more
  • Now Save Rs.3150 on your Demat Account ...Click here
  • Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.